TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04961632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients taking 20mg tamoxifen will receive dose increments of 10mg every 8 weeks until endoxin threshold of \>30nM or the maximum dose of 40mg/day is reached. The escalated dose will be taken for 1 year before reverting back to 20mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients will take tamoxifen at the ascribed genotype-determined dose as determined in the dose-determination phase.
Study: NCT02800447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natulan
Description: Each baseline BEACOPP regimen lasts 21 days, and each cycle consists of： Cyclophosphamide injection: 650mg/m2, IV infusion, day 1； Doxorubicin hydrochloride injection: 25mg/m2, IV infusion, day 1； Etoposide injection: 100mg/m2, IV infusion, day 1\~3; Natulan (procarbazine hydrochloride capsule): 100mg/m2，po, day 1\~7; Bleomycin hydrochloride injection: 10mg/m2, IV or IM, day 8; Vincristine: 1.4mg/m2 (single maximum dose is 2mg), IV infusion, day 8; Prednisone tablet: 40mg/m2, po, day 1\~14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD
Description: Each ABVD cycle lasts 28 days1 cycle of the ABVD regimen consists of： Doxorubicin hydrochloride injection：25mg/m2，IV infusion，day 1 and 15; Dacarbazine injection：375mg/m2，IV infusion，day 1 and 15； Bleomycin injection：10mg/m2，IV or IM，day 1 and 15； Vincristine injection：1.4mg/m2 (single maximum dose is 2mg), IV infusion，day 1 and 15;
Study: NCT04021225

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ectoin® Allergy Eye Drops 2%
Description: A one-time application of 1-2 drops in the more affected eye will be investigated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ectoin® Eye Spray Colloidal
Description: A one-time application of 1-2 drops in the more affected eye will be investigated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tears Again® eye spray
Description: A one-time application of 1-2 drops in the more affected eye will be investigated.
Study: NCT02754336

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cogmed Robomemo, working memory training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Othmer, neurofeedback
Study: NCT02462343

Intervention type: OTHER
Group type: OTHER
Intervention: walk tests

Intervention type: OTHER
Group type: OTHER
Intervention: walk tests
Study: NCT00264563

Intervention type: BEHAVIORAL
Intervention: Increasing the level of awareness to Iatrogenesis
Description: Increasing the level of awareness to Iatrogenesis

Intervention type: BEHAVIORAL
Intervention: Increasing awareness .
Description: Increasing awareness to Iatrogenesis and active daily recordings
Study: NCT02361398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the EIT guide the individualized PEEP Setting
Description: the EIT guide the individualized PEEP Setting in the EIT group
Study: NCT03470545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mavacamten
Description: mavacamten capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo oral capsule
Study: NCT01309477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Sustained-release Capsules (ADVAGRAF)
Description: Started: 0.05-0.1mg/kg/d, one time per day, then adjusting the dose to maintain the blood level 5-10ng/ml in the induction treatment .
Study: NCT01339962

Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional (retrospective chart reviews)
Study: NCT01144962

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.
Description: Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.
Description: Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, with local injection of indicated dose of MSCs

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.
Description: Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, with local injection of indicated dose of MSCs

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.
Description: Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, with local injection of indicated dose of MSCs
Study: NCT00507156

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard primary PCI
Description: Acute re-opening of the occluded coronary artery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical postconditioning
Description: Mechanical postconditioning with 4 cycles 30/30 sek balloon inflations
Study: NCT04351945

Intervention type: PROCEDURE
Intervention: Blood test
Description: Hormone levels will be measured just before transplantation, and three day after the transplantation. In case of the donors hormone levels will be defined during the explantation.
Study: NCT03157908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CareConekta
Description: CareConekta is a smartphone app developed in parallel with a series of focus group discussions that uses global positioning system (GPS) data to identify the user's location to meet two primary functions: (1) to allow the participant to locate ART facilities in South Africa that are near her current location, and (2) to trace mobility prospectively.
Study: NCT01355978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Open Ventilation System
Description: Noninvasive ventilation system
Study: NCT01061190

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: oral application of 160 mg Propranolol for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: oral application of 160 mg Propranolol for 30 days
Study: NCT03230045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupoint stimulation
Description: Acupoint Zhongfu and Zusanli are stimulated through electrodes attached on the skin

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: no treatment
Description: electrodes are attached, but no stimulation is given
Study: NCT03704506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxil capsule simulator
Description: amoxil capsule simulator , 0.5g by mouth , 3 times per day for 7 days
Study: NCT02249507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: aerobic exercise (cycloergometer) at selected intensity (HRmax or equivalent)
Study: NCT05040945

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional corticotomy
Description: Adult patients will be treated by extraction of maxillary first premolars with applying mini-screws between maxillary second premolar and first molar as temporary skeletal anchorage devices (TSADs). Then en-masse retraction associated with traditional corticotomy will be applied.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flapless corticotomy
Description: Adult patients will be treated by extraction of maxillary first premolars with applying mini-screws between maxillary second premolar and first molar as temporary skeletal anchorage devices (TSADs). Then en-masse retraction associated with flapless corticotomy will be applied.
Study: NCT02835092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Take Shape For Life Program
Description: The Take Shape For Life (TSFL) Program group will be assigned to the Optimal Weight 5 \& 1 Plan™ for weight loss. This group will have scheduled coaching sessions with a TSFL coach for the duration of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medifast Direct Program
Description: The Medifast Direct Program (MEDD) group will be assigned to the Medifast Achieve™ Plan (4 \& 2 \& 1 Plan®) for weight loss. MEDD participants will have access to the services of the Medifast Nutrition Support Team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed Control
Description: The Self-directed Control Group will be assigned to a food-based, reduced calorie diet consistent with the 2015 Dietary Guidelines for Americans.
Study: NCT04442347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-810
Description: ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) mRNA formulated in a lipid nanoparticle (LNP) under development.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo for this study is 0.9% sterile saline.
Study: NCT00565838

Intervention type: PROCEDURE
Intervention: AFS and TVT
Description: Autologous Fascial Sling and Tension- Free Vaginal Tape
Study: NCT02547441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS001 (Omiganan)
Description: Topical gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Gel
Study: NCT01427049

Intervention type: DEVICE
Intervention: renal denervation
Description: percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system
Study: NCT02181907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UH-AC 62 XX tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UH-AC 62 XX tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UH-AC 62 XX capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UH-AC 62 XX capsule
Study: NCT01601912

Intervention type: DRUG
Intervention: Atomoxetine
Description: 40 mg, 1 application

Intervention type: DRUG
Intervention: Citalopram
Description: 20 mg, 1 application
Study: NCT03251612

Intervention type: DRUG
Group type: OTHER
Intervention: Based on sensitivity analysis
Description: * 5FU, infusional~* Capecitabine~* Oxaliplatin (FOLFOX)~* Irinotecan (FOLFIRI)~* FOLFOXIRI (triplet)~* Bevacizumab~* Panitumumab~* Cetuximab~* Regorafenib~* Tas-102~* Ramucirumab~* Aflibercept~* Pembrolizumab~* Nivolumab~* Vinorelbine and capecitabine~* Sorafenib~* Gemcitabine and capecitabine~* Olaparib~* Epirubicin
Study: NCT04088864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is a purine antagonist antimetabolite

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is a purine antagonist antimetabolite

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard derivative alkylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard derivative alkylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CD22 CAR T
Description: Autologous T cells transduced with lentiviral vector (m971BBZ) Chimeric Antigen Receptor (CD22 CAR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CD22 CAR T
Description: Autologous T cells transduced with lentiviral vector (m971BBZ) Chimeric Antigen Receptor (CD22 CAR)
Study: NCT04074343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study: NCT03790904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Co.
Description: 15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kin
Description: 15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: 15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
Study: NCT02119949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Description: The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the experimental group executed versions of these task that adapt to their working memory capacity, to train their working memory optimally.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo training
Description: The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the placebo group executed easy versions of these task that did not adapt to their level, to prevent training.
Study: NCT03218566

Intervention type: DEVICE
Group type: OTHER
Intervention: Indigo Aspiration System
Description: use of mechanical thrombectomy to treat pulmonary embolism
Study: NCT03091582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive factors
Description: The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive and behavioral factors on affective distress

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral factors
Description: The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. Behavioral factors on affective distress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase engagement of pleasant events
Description: Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
Study: NCT01710800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01550432

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: 1,130 mg/day or 2,260 mg/day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: 1,130 mg/day or 2,260 mg/day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 600 mg/day or 1,200 mg/day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 600 mg/day or 1,200 mg/day for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume of liquid placebo product comparable to liposomal glutathione and 1 or 2 placebo pills/day.
Study: NCT00144846

Intervention type: DRUG
Group type: OTHER
Intervention: albuterol sulfate inhalation aerosol
Study: NCT00696553

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Nutrition Intervention
Description: Provision of individualized nutrition counseling and nutrition support using oral liquid nutrition supplements and/or liquid enteral supplements

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition plus Exercise
Description: Nutrition plus Exercise
Study: NCT02632812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide effervescent granules
Description: Rebamipide effervescent granules 100mg (oral), twice daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo effervescent granules
Description: Placebo effervescent granules (oral), twice daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen tablet
Description: Naproxen tablet 550mg (tablet), twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen tablet
Description: Naproxen tablet 550mg (tablet), twice daily for 7 days
Study: NCT03416413

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory phlebectomy
Description: Minor surgery to remove varicose vein tributaries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foam sclerotherapy
Description: Injection of foam sclerosant into varicose vein tributaries
Study: NCT03563313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM
Description: Participants will use the Tandem t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM for 6 months at home.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensor-augmented pump (SAP)
Description: Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.
Study: NCT02250534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes
Study: NCT02488083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrashape
Description: circumference reduction
Study: NCT04044703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin - model-based dosing regimen
Description: A dosing calculator based on a population pharmacokinetic model for vancomycin will be used to generate a participant's intermittent vancomycin dosing regimen. The participant's post-menstrual age, weight, creatinine and the target trough vancomycin level will be entered into the dosing calculator and the dose will be generated (intermittent infusion, dosing frequency will be from 1 to 4 times per day according to the corrected gestational age).
Study: NCT02305745

Intervention type: OTHER
Intervention: Observational

Intervention type: OTHER
Intervention: Observational
Study: NCT03579238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CV4
Description: The occiput of a supine patient is held such that flexion motion is inhibited and extension motion is reinforced.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: touching
Description: the clinician allows the participant's head to rest quietly upon his open palms on a table.
Study: NCT03045809

Intervention type: DIAGNOSTIC_TEST
Intervention: Urogenital infection point-of-care tests
Description: Instead of syndromic management of symptomatic women, the study offers screening of high risk women regardless of symptoms using point-of-care tests for HIV, TV, and BV (all women), syphilis, NG, and CT (when risk score positive), and UTI (when symptomatic).
Study: NCT03699813

Intervention type: OTHER
Intervention: Comparison of two approaches to bleeding management

Intervention type: OTHER
Intervention: Comparison of two approaches to bleeding management
Study: NCT02697734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osilodrostat
Description: In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: osilodrostat Placebo
Description: Matching Placebo in the form of filmcoated tablets for oral administration
Study: NCT02030886

Intervention type: DEVICE
Group type: OTHER
Intervention: Sensimed Triggersfish® (TF)
Description: All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
Study: NCT00588939

Intervention type: DEVICE
Intervention: Cell~vizio (Laser connfocal microscopy)
Description: completed during endoscopy
Study: NCT02387424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT-PD
Description: The 8-session MBCT protocol, with modifications for use in the context of pregnancy and in anticipation of the postpartum.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OAR
Description: Ongoing Assessment and Referral (OAR) consists of routine screening and referral to behavioral health services within obstetric clinical settings within Kaiser Permanente (KP) in Colorado and Georgia.
Study: NCT00520052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: 5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: 5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)
Study: NCT02741115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study: NCT02686788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMP001
Description: 600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
Study: NCT01997970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill workstation
Description: The intervention group will receive a treadmill workstation for 12 months. They will use this at self-selected speed and will be recommended to use this for at least 1 hour per day. Participants in the control group will continue with conventional office work at their regular desk. Participants in the intervention group will receive four boosting e-mails during the study period, in which they will be encouraged to use the treadmill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health talk
Description: Participants in both groups will receive a health talk with recommendations about diet and physical activity habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health talk
Description: Participants in both groups will receive a health talk with recommendations about diet and physical activity habits.
Study: NCT05254470

Intervention type: DEVICE
Intervention: Continuous Ultrasound
Description: 3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device
Study: NCT04539756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive psychological intervention
Description: Participants will be asked to complete writing activities every other day. They will choose which activity they would like to complete each day, from a menu of six different activities. Each activity is a different positive psychology exercise.
Study: NCT03817723

Intervention type: RADIATION
Intervention: c-arm cholangiography

Intervention type: RADIATION
Intervention: c-arm cholangiography